<p>DNB Asset Management AS 在最近向證券交易委員會（SEC）提交的 13F 文件中披露，在第四季度將其在 CVS Health Corporation（紐約證券交易所代碼：CVS - 免費報告）的持股增加了 17.6%。該公司在季度內額外購買了 66,953 股後，持有 446,843 股該藥房運營商的股票。根據其最近的 SEC 文件，DNB Asset Management AS 在 CVS Health 的持股價值為 35,461,000 美元。</p>
<ul>
<li>3 只醫療保健股票將從這項重大法案中受益</li>
</ul>
<p>其他一些對沖基金和機構投資者最近也調整了對該公司的持股。先鋒集團（Vanguard Group Inc.）在第四季度將其在 CVS Health 的持股增加了 1.5%。先鋒集團目前持有 120,709,530 股該藥房運營商的股票，價值 9,579,508,000 美元，在此期間又購買了 1,824,424 股。資本世界投資者（Capital World Investors）在第三季度將其在 CVS Health 的持股增加了 2.1%。資本世界投資者目前持有 68,382,158 股該藥房運營商的股票，價值 5,155,380,000 美元，在此期間又購買了 1,419,575 股。州街公司（State Street Corp）在第三季度將其在 CVS Health 的持股增加了 0.3%。州街公司目前持有 58,938,286 股該藥房運營商的股票，價值 4,443,357,000 美元，在此期間又購買了 149,701 股。資本國際投資者（Capital International Investors）在第三季度將其在 CVS Health 的持股增加了 1.1%。資本國際投資者目前持有 26,692,203 股該藥房運營商的股票，價值 2,012,347,000 美元，在上個季度又購買了 302,499 股。最後，景順（Invesco Ltd.）在第三季度將其在 CVS Health 的持股增加了 3.2%。景順目前持有 24,293,058 股該藥房運營商的股票，價值 1,831,454,000 美元，在上個季度又購買了 760,579 股。80.66% 的股票由對沖基金和其他機構投資者持有。</p>
<h2>CVS Health 的內部交易</h2>
<p>在其他新聞中，執行副總裁 Tilak Mandadi 於 5 月 8 日星期五出售了 69,551 股公司的股票。該股票以平均價格 89.58 美元出售，總交易額為 6,230,378.58 美元。出售完成後，該執行副總裁持有 10,133 股公司的股票，價值 907,714.14 美元。這代表其持股減少了 87.28%。該交易已在向證券交易委員會提交的文件中披露，文件可通過此鏈接獲取。公司內部人士持有 0.85% 的公司股票。</p>
<h2>分析師設定新的價格目標</h2>
<ul>
<li>這隻 ETF 證明醫療保健復甦是真實的</li>
</ul>
<p>多家券商最近對 CVS 發佈了報告。TD Cowen 將 CVS Health 的股票目標價從 105.00 美元上調至 110.00 美元，並在 5 月 11 日的研究報告中給予該股票 “買入” 評級。Argus 將 CVS Health 的股票目標價從 90.00 美元上調至 104.00 美元，並在週四的研究報告中給予該股票 “買入” 評級。Leerink Partners 在 3 月 5 日的研究報告中重申了 “跑贏大盤” 評級，並對 CVS Health 的股票設定了 98.00 美元的目標價。華爾街 Zen 在 5 月 9 日的研究報告中將 CVS Health 的股票評級從 “持有” 上調至 “買入”。最後，桑福德·C·伯恩斯坦（Sanford C. Bernstein）在 5 月 12 日的研究報告中將 CVS Health 的股票目標價從 94.00 美元上調至 106.00 美元，並給予該股票 “跑贏大盤” 評級。22 位投資分析師對該股票給予了 “買入” 評級，4 位給予了 “持有” 評級。根據 MarketBeat 的數據，CVS Health 目前的平均評級為 “適度買入”，平均目標價為 98.08 美元。</p>
<p><strong>查看我們關於 CVS Health 的最新研究報告</strong></p>
<h2>CVS Health 的價格表現</h2>
<ul>
<li>CVS Health 收入增長，股息保持強勁</li>
</ul>
<p>CVS 週五開盤價為 95.95 美元。該公司的債務與股本比率為 0.78，速動比率為 0.66，流動比率為 0.87。該股票的市值為 1,224.2 億美元，市盈率為 42.27，市盈增長比率為 0.94，貝塔值為 0.60。該公司的 50 日簡單移動平均線為 78.71 美元，200 日簡單移動平均線為 78.59 美元。CVS Health Corporation 的 52 周低點為 58.50 美元，52 周高點為 98.43 美元。</p>
<p>CVS Health（紐約證券交易所代碼：CVS - 獲取免費報告）最近於 5 月 6 日星期三發佈了其財報。該藥房運營商報告本季度每股收益（EPS）為 2.57 美元，超出市場共識預期的 2.21 美元，超出幅度為 0.36 美元。該公司本季度的收入為 1,004.3 億美元，而分析師預期為 949.9 億美元。CVS Health 的淨利潤率為 0.72%，股本回報率為 11.88%。該公司本季度的收入較去年同期增長了 6.2%。在去年同期，該公司每股收益為 2.25 美元。CVS Health 將其 2026 財年的指引設定為每股收益 7.300-7.500 美元。整體來看，分析師預測 CVS Health Corporation 本年度將發佈每股收益 7.44 美元。</p>
<h2>CVS Health 宣佈分紅</h2>
<p>該公司最近還宣佈了季度分紅，於 5 月 4 日星期一支付。4 月 23 日的股東獲得了每股 0.665 美元的分紅。除息日期為 4 月 23 日。這代表每年 2.66 美元的分紅，收益率為 2.8%。CVS Health 的分紅支付比率目前為 117.18%。</p>
<h2>CVS Health 新聞摘要</h2>
<p>以下是本週影響 CVS Health 的主要新聞故事：</p>
<ul>
<li>積極情緒：摩根士丹利上調了對 CVS Health 的目標股價，並維持了增持評級，顯示出對公司強於預期的季度業績後進一步上漲的信心。摩根士丹利發佈 CVS Health 的積極預測 NYSE: CVS 股價</li>
<li>積極情緒：Argus 也提高了對 CVS Health 的展望，進一步增加了分析師支持的浪潮，這可能幫助股價上漲。Argus 發佈 CVS Health 的積極預測 NYSE: CVS 股價</li>
<li>積極情緒：CVS 最近公佈了 2026 年第一季度的強勁財報，收入和調整後的每股收益均超出預期，這繼續推動投資者對執行和估值的樂觀情緒。以下是為什麼 CVS Health (CVS) 是未來 10 年值得購買的便宜股票</li>
<li>積極情緒：CVS 與 WGU 推出了一項在線藥學預科學位項目，以幫助建立更強大的藥劑師人才管道，這一舉措可能支持長期的人員和服務增長。CVS Health®與 WGU 在全國範圍內推出在線藥學預科學位項目</li>
<li>中性情緒：CVS 通過在破產法庭批准後出售 Omnicare 推進了其投資組合重組，這簡化了業務並剔除了一個表現不佳的部門，但也確認了持續的重組。CVS 通過 Omnicare 出售和無人機推廣重新聚焦核心健康平台</li>
<li>中性情緒：CVS 還強調了在羅德島的社區和品牌建設舉措，包括其經濟影響報告和擴大 WIC 接受度，這對聲譽有積極影響，但不太可能單獨推動股價。CVS Health 在羅德島的年度影響</li>
</ul>
<h2>CVS Health 公司簡介</h2>
<p>(免費報告)</p>
<p>CVS Health Corporation 是一家多元化的醫療保健公司，運營着一個大型零售藥房網絡、藥房福利管理服務和醫療解決方案。公司總部位於羅德島的伍恩索克特，其根源可以追溯到 20 世紀 60 年代初，已發展成為一個綜合提供處方藥、非處方產品、臨牀服務和健康保險的供應商。其運營模式結合了零售藥房位置和店內診所與更廣泛的藥房和健康計劃能力。</p>
<p>主要業務活動包括 CVS 藥房零售業務、MinuteClinic 步入式醫療診所和提供擴展臨牀服務的 HealthHUB 地點。</p>
<h2>進一步閲讀</h2>
<ul>
<li>五隻我們更看好的股票，勝過 CVS Health</li>
<li>如果油價持續上漲，值得擁有的三隻股票</li>
<li>分析師青睞的三家關鍵航空航天組件製造商</li>
<li>Alphabet 的 Googlebook 將 Gemini AI 引入 PC 硬件</li>
<li>Peloton 股票在樂觀財報後回吐漲幅</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNWUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNWUw"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資$1,000 在 CVS Health 嗎？</h2>
<p>在考慮 CVS Health 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 CVS Health 並不在名單上。</p>
<p>雖然 CVS Health 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

西維斯

<p>DNB 資產管理公司在第四季度將其在 CVS Health Corporation 的持股增加了 17.6%，目前擁有 446,843 股，價值 3546 萬美元。其他機構投資者也提高了他們的持股比例。分析師們為 CVS 設定了新的價格目標，許多人將其評級為 “買入”。CVS Health 的股票開盤價為 95.95 美元，市值為 1224.2 億美元，市盈率為 42.27</p>

<p>DNB Asset Management AS lifted its holdings in CVS Health Corporation (NYSE:CVS - Free Report) by 17.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 446,843 shares of the pharmacy operator's stock after buying an additional 66,953 shares during the quarter. DNB Asset Management AS's holdings in CVS Health were worth $35,461,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>DNB Asset Management AS 在最近向證券交易委員會（SEC）提交的 13F 文件中披露，在第四季度將其在 CVS Health Corporation（紐約證券交易所代碼：CVS - 免費報告）的持股增加了 17.6%。該公司在季度內額外購買了 66,953 股後，持有 446,843 股該藥房運營商的股票。根據其最近的 SEC 文件，DNB Asset Management AS 在 CVS Health 的持股價值為 35,461,000 美元。</p>
</div><ul>
<li>3 Healthcare Stocks Set to Benefit From the One Big Beautiful Bill</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只醫療保健股票將從這項重大法案中受益</li>
</ul>
</div><p>A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Vanguard Group Inc. grew its position in shares of CVS Health by 1.5% in the 4th quarter. Vanguard Group Inc. now owns 120,709,530 shares of the pharmacy operator's stock worth $9,579,508,000 after buying an additional 1,824,424 shares during the period. Capital World Investors grew its position in shares of CVS Health by 2.1% in the 3rd quarter. Capital World Investors now owns 68,382,158 shares of the pharmacy operator's stock worth $5,155,380,000 after buying an additional 1,419,575 shares during the period. State Street Corp grew its position in shares of CVS Health by 0.3% in the 3rd quarter. State Street Corp now owns 58,938,286 shares of the pharmacy operator's stock worth $4,443,357,000 after buying an additional 149,701 shares during the period. Capital International Investors boosted its stake in CVS Health by 1.1% in the 3rd quarter. Capital International Investors now owns 26,692,203 shares of the pharmacy operator's stock worth $2,012,347,000 after purchasing an additional 302,499 shares in the last quarter. Finally, Invesco Ltd. boosted its stake in CVS Health by 3.2% in the 3rd quarter. Invesco Ltd. now owns 24,293,058 shares of the pharmacy operator's stock worth $1,831,454,000 after purchasing an additional 760,579 shares in the last quarter. 80.66% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他一些對沖基金和機構投資者最近也調整了對該公司的持股。先鋒集團（Vanguard Group Inc.）在第四季度將其在 CVS Health 的持股增加了 1.5%。先鋒集團目前持有 120,709,530 股該藥房運營商的股票，價值 9,579,508,000 美元，在此期間又購買了 1,824,424 股。資本世界投資者（Capital World Investors）在第三季度將其在 CVS Health 的持股增加了 2.1%。資本世界投資者目前持有 68,382,158 股該藥房運營商的股票，價值 5,155,380,000 美元，在此期間又購買了 1,419,575 股。州街公司（State Street Corp）在第三季度將其在 CVS Health 的持股增加了 0.3%。州街公司目前持有 58,938,286 股該藥房運營商的股票，價值 4,443,357,000 美元，在此期間又購買了 149,701 股。資本國際投資者（Capital International Investors）在第三季度將其在 CVS Health 的持股增加了 1.1%。資本國際投資者目前持有 26,692,203 股該藥房運營商的股票，價值 2,012,347,000 美元，在上個季度又購買了 302,499 股。最後，景順（Invesco Ltd.）在第三季度將其在 CVS Health 的持股增加了 3.2%。景順目前持有 24,293,058 股該藥房運營商的股票，價值 1,831,454,000 美元，在上個季度又購買了 760,579 股。80.66% 的股票由對沖基金和其他機構投資者持有。</p>
</div><h2>Insider Transactions at CVS Health</h2>
<div class="lb-trans"><h2>CVS Health 的內部交易</h2>
</div><p>In other news, EVP Tilak Mandadi sold 69,551 shares of the company's stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the completion of the sale, the executive vice president owned 10,133 shares of the company's stock, valued at $907,714.14. This represents a 87.28% decrease in their position. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through this link. Corporate insiders own 0.85% of the company's stock.</p>
<div class="lb-trans"><p>在其他新聞中，執行副總裁 Tilak Mandadi 於 5 月 8 日星期五出售了 69,551 股公司的股票。該股票以平均價格 89.58 美元出售，總交易額為 6,230,378.58 美元。出售完成後，該執行副總裁持有 10,133 股公司的股票，價值 907,714.14 美元。這代表其持股減少了 87.28%。該交易已在向證券交易委員會提交的文件中披露，文件可通過此鏈接獲取。公司內部人士持有 0.85% 的公司股票。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新的價格目標</h2>
</div><ul>
<li>This ETF Is Proof That the Healthcare Rebound Is Real</li>
</ul>
<div class="lb-trans"><ul>
<li>這隻 ETF 證明醫療保健復甦是真實的</li>
</ul>
</div><p>A number of brokerages recently issued reports on CVS. TD Cowen upped their price target on shares of CVS Health from $105.00 to $110.00 and gave the stock a &#34;buy&#34; rating in a research note on Monday, May 11th. Argus upped their price target on shares of CVS Health from $90.00 to $104.00 and gave the stock a &#34;buy&#34; rating in a research note on Thursday. Leerink Partners reiterated an &#34;outperform&#34; rating and issued a $98.00 price target on shares of CVS Health in a research note on Thursday, March 5th. Wall Street Zen upgraded shares of CVS Health from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research note on Saturday, May 9th. Finally, Sanford C. Bernstein upped their price target on shares of CVS Health from $94.00 to $106.00 and gave the stock an &#34;outperform&#34; rating in a research note on Tuesday, May 12th. Twenty-two investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company's stock. According to data from MarketBeat, CVS Health presently has an average rating of &#34;Moderate Buy&#34; and an average price target of $98.08.</p>
<div class="lb-trans"><p>多家券商最近對 CVS 發佈了報告。TD Cowen 將 CVS Health 的股票目標價從 105.00 美元上調至 110.00 美元，並在 5 月 11 日的研究報告中給予該股票 “買入” 評級。Argus 將 CVS Health 的股票目標價從 90.00 美元上調至 104.00 美元，並在週四的研究報告中給予該股票 “買入” 評級。Leerink Partners 在 3 月 5 日的研究報告中重申了 “跑贏大盤” 評級，並對 CVS Health 的股票設定了 98.00 美元的目標價。華爾街 Zen 在 5 月 9 日的研究報告中將 CVS Health 的股票評級從 “持有” 上調至 “買入”。最後，桑福德·C·伯恩斯坦（Sanford C. Bernstein）在 5 月 12 日的研究報告中將 CVS Health 的股票目標價從 94.00 美元上調至 106.00 美元，並給予該股票 “跑贏大盤” 評級。22 位投資分析師對該股票給予了 “買入” 評級，4 位給予了 “持有” 評級。根據 MarketBeat 的數據，CVS Health 目前的平均評級為 “適度買入”，平均目標價為 98.08 美元。</p>
</div><p><strong>Check Out Our Latest Research Report on CVS Health</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 CVS Health 的最新研究報告</strong></p>
</div><h2>CVS Health Price Performance</h2>
<div class="lb-trans"><h2>CVS Health 的價格表現</h2>
</div><ul>
<li>CVS Health Gains as Revenue Grows, Dividend Remains Strong</li>
</ul>
<div class="lb-trans"><ul>
<li>CVS Health 收入增長，股息保持強勁</li>
</ul>
</div><p>CVS opened at $95.95 on Friday. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.66 and a current ratio of 0.87. The stock has a market capitalization of $122.42 billion, a P/E ratio of 42.27, a P/E/G ratio of 0.94 and a beta of 0.60. The company's 50-day simple moving average is $78.71 and its two-hundred day simple moving average is $78.59. CVS Health Corporation has a 52-week low of $58.50 and a 52-week high of $98.43.</p>
<div class="lb-trans"><p>CVS 週五開盤價為 95.95 美元。該公司的債務與股本比率為 0.78，速動比率為 0.66，流動比率為 0.87。該股票的市值為 1,224.2 億美元，市盈率為 42.27，市盈增長比率為 0.94，貝塔值為 0.60。該公司的 50 日簡單移動平均線為 78.71 美元，200 日簡單移動平均線為 78.59 美元。CVS Health Corporation 的 52 周低點為 58.50 美元，52 周高點為 98.43 美元。</p>
</div><p>CVS Health (NYSE:CVS - Get Free Report) last posted its earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.21 by $0.36. The business had revenue of $100.43 billion for the quarter, compared to analysts' expectations of $94.99 billion. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The business's revenue for the quarter was up 6.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.25 EPS. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. As a group, analysts predict that CVS Health Corporation will post 7.44 EPS for the current year.</p>
<div class="lb-trans"><p>CVS Health（紐約證券交易所代碼：CVS - 獲取免費報告）最近於 5 月 6 日星期三發佈了其財報。該藥房運營商報告本季度每股收益（EPS）為 2.57 美元，超出市場共識預期的 2.21 美元，超出幅度為 0.36 美元。該公司本季度的收入為 1,004.3 億美元，而分析師預期為 949.9 億美元。CVS Health 的淨利潤率為 0.72%，股本回報率為 11.88%。該公司本季度的收入較去年同期增長了 6.2%。在去年同期，該公司每股收益為 2.25 美元。CVS Health 將其 2026 財年的指引設定為每股收益 7.300-7.500 美元。整體來看，分析師預測 CVS Health Corporation 本年度將發佈每股收益 7.44 美元。</p>
</div><h2>CVS Health Announces Dividend</h2>
<div class="lb-trans"><h2>CVS Health 宣佈分紅</h2>
</div><p>The business also recently announced a quarterly dividend, which was paid on Monday, May 4th. Shareholders of record on Thursday, April 23rd were paid a dividend of $0.665 per share. The ex-dividend date was Thursday, April 23rd. This represents a $2.66 annualized dividend and a yield of 2.8%. CVS Health's dividend payout ratio is currently 117.18%.</p>
<div class="lb-trans"><p>該公司最近還宣佈了季度分紅，於 5 月 4 日星期一支付。4 月 23 日的股東獲得了每股 0.665 美元的分紅。除息日期為 4 月 23 日。這代表每年 2.66 美元的分紅，收益率為 2.8%。CVS Health 的分紅支付比率目前為 117.18%。</p>
</div><h2>CVS Health News Summary</h2>
<div class="lb-trans"><h2>CVS Health 新聞摘要</h2>
</div><p>Here are the key news stories impacting CVS Health this week:</p>
<div class="lb-trans"><p>以下是本週影響 CVS Health 的主要新聞故事：</p>
</div><ul>
<li>Positive Sentiment: Morgan Stanley raised its price target on CVS Health and kept an overweight rating, signaling confidence in further upside after the company’s stronger-than-expected quarterly results. Morgan Stanley Issues Positive Forecast for CVS Health NYSE: CVS Stock Price</li>
<li>Positive Sentiment: Argus also lifted its outlook for CVS Health, adding to the wave of analyst support that may be helping shares move higher. Argus Issues Positive Forecast for CVS Health NYSE: CVS Stock Price</li>
<li>Positive Sentiment: CVS reported solid Q1 2026 earnings recently, beating estimates on both revenue and adjusted EPS, which continues to drive investor optimism about execution and valuation. Here is Why CVS Health (CVS) is One of the Cheap Stocks to Buy For the Next 10 Years</li>
<li>Positive Sentiment: CVS and WGU launched an online pre-pharmacy degree program to help build a stronger pharmacist pipeline, a move that could support long-term staffing and service growth. CVS Health® and WGU launch online pre-pharmacy degree program for future pharmacists nationwide</li>
<li>Neutral Sentiment: CVS advanced its portfolio reset by selling Omnicare after bankruptcy court approval, which simplifies the business and removes an underperforming unit, but also confirms ongoing restructuring. CVS Refocuses On Core Health Platform With Omnicare Sale And Drone Rollout</li>
<li>Neutral Sentiment: CVS also highlighted community and brand-building initiatives in Rhode Island, including its economic impact report and expanded WIC acceptance, which are positive for reputation but less likely to move the stock on their own. CVS Health’s Annual Impact in Rhode Island</li>
</ul>
<div class="lb-trans"><ul>
<li>積極情緒：摩根士丹利上調了對 CVS Health 的目標股價，並維持了增持評級，顯示出對公司強於預期的季度業績後進一步上漲的信心。摩根士丹利發佈 CVS Health 的積極預測 NYSE: CVS 股價</li>
<li>積極情緒：Argus 也提高了對 CVS Health 的展望，進一步增加了分析師支持的浪潮，這可能幫助股價上漲。Argus 發佈 CVS Health 的積極預測 NYSE: CVS 股價</li>
<li>積極情緒：CVS 最近公佈了 2026 年第一季度的強勁財報，收入和調整後的每股收益均超出預期，這繼續推動投資者對執行和估值的樂觀情緒。以下是為什麼 CVS Health (CVS) 是未來 10 年值得購買的便宜股票</li>
<li>積極情緒：CVS 與 WGU 推出了一項在線藥學預科學位項目，以幫助建立更強大的藥劑師人才管道，這一舉措可能支持長期的人員和服務增長。CVS Health®與 WGU 在全國範圍內推出在線藥學預科學位項目</li>
<li>中性情緒：CVS 通過在破產法庭批准後出售 Omnicare 推進了其投資組合重組，這簡化了業務並剔除了一個表現不佳的部門，但也確認了持續的重組。CVS 通過 Omnicare 出售和無人機推廣重新聚焦核心健康平台</li>
<li>中性情緒：CVS 還強調了在羅德島的社區和品牌建設舉措，包括其經濟影響報告和擴大 WIC 接受度，這對聲譽有積極影響，但不太可能單獨推動股價。CVS Health 在羅德島的年度影響</li>
</ul>
</div><h2>CVS Health Company Profile</h2>
<div class="lb-trans"><h2>CVS Health 公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免費報告)</p>
</div><p>CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.</p>
<div class="lb-trans"><p>CVS Health Corporation 是一家多元化的醫療保健公司，運營着一個大型零售藥房網絡、藥房福利管理服務和醫療解決方案。公司總部位於羅德島的伍恩索克特，其根源可以追溯到 20 世紀 60 年代初，已發展成為一個綜合提供處方藥、非處方產品、臨牀服務和健康保險的供應商。其運營模式結合了零售藥房位置和店內診所與更廣泛的藥房和健康計劃能力。</p>
</div><p>Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.</p>
<div class="lb-trans"><p>主要業務活動包括 CVS 藥房零售業務、MinuteClinic 步入式醫療診所和提供擴展臨牀服務的 HealthHUB 地點。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than CVS Health</li>
<li>3 Stocks to Own If Gas Prices Keep Rising</li>
<li>3 Crucial Aerospace Component Makers That Analysts Love</li>
<li>Alphabet's Googlebook Brings Gemini AI to PC Hardware</li>
<li>Peloton Stock Gives Back Gains After Upbeat Earnings Report</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 CVS Health</li>
<li>如果油價持續上漲，值得擁有的三隻股票</li>
<li>分析師青睞的三家關鍵航空航天組件製造商</li>
<li>Alphabet 的 Googlebook 將 Gemini AI 引入 PC 硬件</li>
<li>Peloton 股票在樂觀財報後回吐漲幅</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNWUw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=CVS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in CVS Health Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 CVS Health 嗎？</h2>
</div><p>Before you consider CVS Health, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 CVS Health 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 CVS Health 並不在名單上。</p>
</div><p>While CVS Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 CVS Health 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

DNB Asset Management AS Grows Holdings in CVS Health Corporation $CVS

DNB 資產管理公司增持了 CVS Health Corporation 的股份 $CVS